Fidelity Investments
ZIVO

Fidelity Investments’s Zivo Bioscience, Inc. Common Stock ZIVO Stock Holding History

Fidelity Investments’s Portfolio ZIVO Stock Details ZIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-5
Closed – – 5538
2022
Q2 		$0 Sell
5
-2
-29% -$40 ﹤0.01% 5640
2022
Q1 		$0 Buy
+7
New +$139 ﹤0.01% 5638

Other funds holding ZIVO

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
VCA
Verdence Capital Advisors Hunt Valley, Maryland $1.72B AUM 24.88% 1-Year Est. Return
BC
Bartlett & Co Cincinnati, Ohio $6.16B AUM 20.29% 1-Year Est. Return
BCWM
Bartlett & Co Wealth Management Cincinnati, Ohio $7.82B AUM 15.4% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Fidelity Investments's ZIVO Position: Q3 2022 in Review

Fidelity Investments sold out of Zivo Bioscience, Inc. Common Stock (ZIVO) in Q3 2022, closing a stake of 5 shares.

Fidelity Investments first reported a position in ZIVO in Q1 2022 and held it in 2 quarters. The position peaked at $0 in Q2 2022. 12 funds tracked by Wall St. Rank hold ZIVO as of Q3 2022.

  • Fidelity Investments reported no remaining Zivo Bioscience, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Fidelity Investments sold 5 Zivo Bioscience, Inc. Common Stock shares in Q3 2022.
  • Fidelity Investments first reported a position in Zivo Bioscience, Inc. Common Stock in Q1 2022 and held it in 2 quarters.
  • Fidelity Investments's Zivo Bioscience, Inc. Common Stock position peaked at $0 in Q2 2022.
  • 12 funds tracked by Wall St. Rank held Zivo Bioscience, Inc. Common Stock as of Q3 2022.

Based on Fidelity Investments's 13F filing for Q3 2022, filed 10 Nov 2022.